Feb 7, 2025 · EMBLAVEO TM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra ... AbbVie cautions that …

EMBLAVEO for complicated intra-abdominal infections in adults caused by designated susceptible gram-negative microorganisms. See full Prescribing Information.

3 days ago · AbbVie warns that Emblaveo is contraindicated in patients with known hypersensitivity to aztreonam and avibactam. Additionally, adverse events (AEs) included …

AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in conjunction with metronidazole for people aged 18 and over with …

NORTH CHICAGO, Ill., Feb. 7, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam …

5 days ago · AbbVie expects Emblaveo to become available in the third quarter of this year. The company did not reveal its price. “As bacteria evolve, industry, government, and clinical …

Feb 7, 2025 · The US FDA today approved Emblaveo™ (aztreonam and avibactam; AbbVie), a novel fixed-dose, intravenous antibiotic combination, for the treatment of complicated intra …

4 days ago · NORTH CHICAGO - AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO (aztreonam and avibactam), as the …

Aztreonam/avibactam, sold under the brand name Emblaveo, is a fixed-dose combination antibacterial medication used for the treatment of aerobic Gram-negative infections. [4] It is a …

5 days ago · Emblaveo, a new combination antibiotic developed in a partnership between AbbVie and Pfizer, received FDA approval to address difficult-to-treat intra-abdominal bacterial …